Side-by-side comparison of AI visibility scores, market position, and capabilities
Iconic 99-cent iced tea brand maintaining its price since 1992; $1B+ revenue from value-positioned ready-to-drink teas with cult consumer loyalty competing with Lipton and Snapple.
Arizona (AriZona Beverage Company) is an American beverage company best known for its iconic 99-cent tall cans of iced tea — particularly the Arizona Green Tea with Ginseng and Honey and Arizona Arnold Palmer (half iced tea, half lemonade) — which have maintained the same 99-cent price since the product's introduction in 1992, making them a cult favorite for value-conscious consumers. Founded in 1992 by Don Vultaggio and John Ferolito in Brooklyn, New York and headquartered in Woodbury, New York, AriZona generates approximately $1+ billion in annual revenue and is privately held.\n\nAriZona's product lineup spans iced teas, fruit juices, energy drinks (AriZona Energy), water, lemonades, and smoothies — all characterized by the distinctive Southwestern-themed packaging with sun and cactus motifs designed by Vultaggio himself. The company keeps costs low through efficient manufacturing, limited marketing spend (relying on word-of-mouth and its iconic brand recognition), and maintaining large package sizes at low price points that deliver perceived value.\n\nIn 2025, AriZona's 99-cent price point has become a cultural phenomenon — the company has resisted inflation pressure that has forced virtually every other beverage brand to raise prices, creating enormous brand loyalty and social media attention. AriZona competes with Lipton Iced Tea (Unilever-PepsiCo), Snapple (Keurig Dr Pepper), and energy drinks like Red Bull and Monster for ready-to-drink beverage shelf space. The company's 2025 strategy maintains its core value positioning, expands its energy and wellness product lines, and continues international distribution growth while keeping its beloved flagship price frozen at 99 cents.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.